Trial Profile

TrimetaziDine as a Performance-enhancING drug in Heart Failure with Preserved Ejection Fraction

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trimetazidine (Primary)
Indications Heart failure
Focus Therapeutic Use
Acronyms DoPING-HFpEF

Most Recent Events

07 Nov 2022 Results assessing whether trimetazidine, can improve cardiac energy homeostasis and consequently improve diastolic function, presented at the American Heart Association Scientific Sessions 2022.
29 Aug 2022 Primary endpoint has not been met, (Exercise PCWP measured by RHC (gold standard for the evaluation of LV diastology) as per Results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
29 Aug 2022 Results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com